Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1983;11(2):106-7.
doi: 10.1007/BF00254256.

Combination chemotherapy (high-dose methotrexate with citrovorum factor rescue, mechlorethamine, and procarbazine) in non-small cell lung cancer

R R Bhasin, C P Nogeirie

Combination chemotherapy (high-dose methotrexate with citrovorum factor rescue, mechlorethamine, and procarbazine) in non-small cell lung cancer

R R Bhasin et al. Cancer Chemother Pharmacol. 1983.

Abstract

Twenty-five patients with non-small cell lung cancer (NSCLC) were treated with high-dose methotrexate with citrovorum factor resuce (HDMTX-CFR), mechlorethamine (HN2) and procarbazine (PCZ). Nineteen patients are evaluable for response. One patient had partial remission which lasted for 11 weeks. Nine patients had stable disease lasting for 6-22 weeks. HDMTX-CFR was well tolerated by these patients but this combination regimen produced very low tumor response rate (5.2%). Addition of HN2 and PCZ, chemotherapeutic agents active against NSCLC, failed to improve the tumor response rate but added to gastrointestinal and hematologic toxicity.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Cancer Treat Rep. 1978 Sep;62(9):1295-304 - PubMed
    1. Cancer Chemother Rep 3. 1973 Mar;4(2):177-88 - PubMed
    1. Cancer Treat Rep. 1978 Oct;62(10):1595-7 - PubMed
    1. Cancer Chemother Rep. 1969 Apr;53(2):135-45 - PubMed
    1. Cancer Treat Rep. 1980 Oct-Nov;64(10-11):1017-21 - PubMed

MeSH terms

LinkOut - more resources